Biogen discontinuing natalizumab for stroke after Phase IIb miss

Biogen Inc. (NASDAQ:BIIB) discontinued development of natalizumab to treat acute ischemic stroke after the drug missed the primary and secondary endpoints in the Phase IIb

Read the full 256 word article

How to gain access

Continue reading with a
two-week free trial.